Ross Osborn
Stock Analyst at Cantor Fitzgerald
(2.21)
# 2,610
Out of 4,784 analysts
108
Total ratings
35.79%
Success rate
-1.64%
Average return
Main Sectors:
Stocks Rated by Ross Osborn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SMTI Sanara MedTech | Reiterates: Overweight | $46 | $30.19 | +52.37% | 6 | Mar 26, 2025 | |
| LUCD Lucid Diagnostics | Reiterates: Overweight | $2 | $1.58 | +26.58% | 5 | Mar 26, 2025 | |
| ELUT Elutia | Reiterates: Overweight | $8 | $2.64 | +203.03% | 10 | Mar 7, 2025 | |
| AXGN Axogen | Reiterates: Overweight | $24 | $18.36 | +30.72% | 3 | Mar 5, 2025 | |
| NPCE NeuroPace | Maintains: Overweight | $19 → $20 | $11.85 | +68.78% | 5 | Mar 5, 2025 | |
| MDXG MiMedx Group | Reiterates: Overweight | $13 | $7.54 | +72.41% | 3 | Feb 27, 2025 | |
| SIBN SI-BONE | Reiterates: Overweight | $25 | $14.04 | +78.06% | 8 | Feb 25, 2025 | |
| CERS Cerus | Reiterates: Overweight | $4 | $1.42 | +181.69% | 4 | Feb 21, 2025 | |
| PRE Prenetics Global | Reiterates: Overweight | $9 | $4.00 | +125.00% | 7 | Jan 16, 2025 | |
| XGN Exagen | Reiterates: Overweight | $8 | $3.84 | +108.33% | 5 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $3.80 | +136.84% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $8.73 | +140.55% | 10 | Dec 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $12 | $5.23 | +129.45% | 10 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $7.65 | +109.15% | 4 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 | $12.49 | +12.09% | 2 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $96 | $83.05 | +15.59% | 1 | Oct 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3.5 | $1.14 | +207.02% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $2.5 | $0.55 | +354.55% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $3.58 | - | 7 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3.3 | $0.11 | +3,036.88% | 5 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $4.50 | +11.11% | 2 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8.61 | $0.75 | +1,048.00% | 2 | Aug 18, 2023 |
Sanara MedTech
Mar 26, 2025
Reiterates: Overweight
Price Target: $46
Current: $30.19
Upside: +52.37%
Lucid Diagnostics
Mar 26, 2025
Reiterates: Overweight
Price Target: $2
Current: $1.58
Upside: +26.58%
Elutia
Mar 7, 2025
Reiterates: Overweight
Price Target: $8
Current: $2.64
Upside: +203.03%
Axogen
Mar 5, 2025
Reiterates: Overweight
Price Target: $24
Current: $18.36
Upside: +30.72%
NeuroPace
Mar 5, 2025
Maintains: Overweight
Price Target: $19 → $20
Current: $11.85
Upside: +68.78%
MiMedx Group
Feb 27, 2025
Reiterates: Overweight
Price Target: $13
Current: $7.54
Upside: +72.41%
SI-BONE
Feb 25, 2025
Reiterates: Overweight
Price Target: $25
Current: $14.04
Upside: +78.06%
Cerus
Feb 21, 2025
Reiterates: Overweight
Price Target: $4
Current: $1.42
Upside: +181.69%
Prenetics Global
Jan 16, 2025
Reiterates: Overweight
Price Target: $9
Current: $4.00
Upside: +125.00%
Exagen
Jan 13, 2025
Reiterates: Overweight
Price Target: $8
Current: $3.84
Upside: +108.33%
Jan 7, 2025
Initiates: Overweight
Price Target: $9
Current: $3.80
Upside: +136.84%
Dec 24, 2024
Reiterates: Overweight
Price Target: $21
Current: $8.73
Upside: +140.55%
Dec 6, 2024
Maintains: Overweight
Price Target: $11 → $12
Current: $5.23
Upside: +129.45%
Nov 5, 2024
Reiterates: Overweight
Price Target: $16
Current: $7.65
Upside: +109.15%
Oct 23, 2024
Reiterates: Overweight
Price Target: $14
Current: $12.49
Upside: +12.09%
Oct 15, 2024
Initiates: Neutral
Price Target: $96
Current: $83.05
Upside: +15.59%
Aug 8, 2024
Reiterates: Overweight
Price Target: $3.5
Current: $1.14
Upside: +207.02%
May 16, 2024
Reiterates: Overweight
Price Target: $2.5
Current: $0.55
Upside: +354.55%
Apr 12, 2024
Reiterates: Neutral
Price Target: n/a
Current: $3.58
Upside: -
Apr 10, 2024
Reiterates: Neutral
Price Target: $3.3
Current: $0.11
Upside: +3,036.88%
Mar 1, 2024
Reiterates: Overweight
Price Target: $5
Current: $4.50
Upside: +11.11%
Aug 18, 2023
Reiterates: Neutral
Price Target: $8.61
Current: $0.75
Upside: +1,048.00%